Recent Publications

• 1. Grever M
  2. Andritsos L
  3. Anghelina M
  4. Arons E
  5. Banerji V
  6. Barrientos J
  7. Bhat SA
  8. Blachly J
  9. Broccoli A
  10. Call T
  11. Dearden C
  12. Dietrich S
  13. Else M
  14. Epperla N
  15. Fagarasanu A
  16. Falini B
  17. Forconi F
  18. Gozzetti A
  19. Hampel P
  20. Hermel DJ
  21. Iyengar S
  22. Johnston JB
  23. Juliusson G
  24. Kreitman RJ
  25. Lauria F
  26. Lozanski G
  27. Oakes CC
  28. Parikh SA
  29. Park J
  30. Quest G
  31. Rai K
  32. Ravandi F
  33. Robak T
  34. Rogers KA
  35. Saven A
  36. Seymour JF
  37. Tadmor T
  38. Tallman MS
  39. Tam CS
  40. Tiacci E
  41. Troussard X
  42. Wörmann B
  43. Zent CS
  44. Zenz T
  45. Zinzani PL
  Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms.; Leukemia. 2024 Jun 08.
• 1. Ojo A
  2. Goldenberg I
  3. McNitt S
  4. Schleede S
  5. Casulo C
  6. Zent CS
  7. Moore J
  8. Soniwala M
  9. Aktas MK
  10. Sherazi S
  Risk of New-Onset Atrial Fibrillation Associated With Targeted Treatment of Lymphoma.; JACC. Advances; Vol 2(8), pp. 100602. 2023 Sep 12.
• 1. Van Wagoner CM
  2. Rivera-Escalera F
  3. Jaimes-Delgadillo NC
  4. Chu CC
  5. Zent CS
  6. Elliott MR
  Antibody-mediated phagocytosis in cancer immunotherapy.; Immunological reviews. 2023 Aug 21.
• 1. Brady MT
  2. Laniewski N
  3. Strawderman M
  4. Chu CC
  5. Kanagaiah P
  6. Sangster MY
  7. Topham DJ
  8. Friedberg JW
  9. Zent CS
  Long-term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial Bruton tyrosine kinase inhibitors therapy for chronic lymphocytic leukemia or lymphoplasmacytic lymphoma.; American journal of hematology. 2023 Jul 23.
• 1. Thapa K
  2. Strawderman M
  3. Reagan PM
  4. Barr PM
  5. Zent CS
  6. Friedberg JW
  7. Faugh T
  8. Casulo C
  Healthcare Utilization Disparities of Adolescent and Young Adults Compared to the Older Lymphoma Population.; Clinical lymphoma, myeloma & leukemia. 2023 May 23.
• 1. Moore JE
  2. Bloom PC
  3. Chu CC
  4. Bruno JE
  5. Herne CA
  6. Baran AM
  7. Quataert SA
  8. Mosmann TR
  9. Taylor RP
  10. Wallace DS
  11. Elliott MR
  12. Barr PM
  13. Zent CS
  Rituximab induced cytokine release with high serum IP-10 (CXCL10) concentrations is associated with infusion reactions.; Leukemia research; Vol 129, pp. 107072. 2023 Mar 29.
• 1. Sherazi S
  2. Schleede S
  3. McNitt S
  4. Casulo C
  5. Moore JE
  6. Storozynsky E
  7. Patel A
  8. Vidula N
  9. Aktas MK
  10. Zent CS
  11. Goldenberg I
  Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders.; Journal of the American Heart Association. 2023 Mar 09.
• 1. Archibald WJ
  2. Baran AM
  3. Williams AM
  4. Salloum RM
  5. Richard Burack W
  6. Evans AG
  7. Syposs CR
  8. Zent CS
  The role of splenectomy in management of splenic B-cell lymphomas.; Leukemia research; Vol 128, pp. 107053. 2023 Mar 02.
• 1. Epperla N
  2. Zhao Q
  3. Anghelina M
  4. Neal J
  5. Blachly JS
  6. Rogers KA
  7. Lozanski G
  8. Oakes CC
  9. Bhat SA
  10. Zent CS
  11. Banerji V
  12. Grever M
  13. Andritsos L
  Impact of sex on outcomes in patients with Hairy cell leukemia. An HCL Patient Data Registry analysis.; American journal of hematology. 2023 Feb 20.
• 1. Wallace DS
  2. Zent CS
  3. Baran AM
  4. Reagan PM
  5. Casulo C
  6. Rice G
  7. Friedberg JW
  8. Barr PM
  Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab for Initial Therapy of Chronic Lymphocytic Leukemia.; Blood advances. 2023 Jan 23.
• 1. Hill BT
  2. Ma S
  3. Zent CS
  4. Baran AM
  5. Wallace DS
  6. Advani AS
  7. Winter AM
  8. Winter JN
  9. Gordon LI
  10. Karmali R
  11. Liesveld JL
  12. Mulford DA
  13. Rowland C
  14. Bui A
  15. Sportelli P
  16. Miskin HP
  17. Weiss MS
  18. Friedberg JW
  19. Barr PM
  Response-Adapted, Time-Limited Venetoclax, Umbralisib and Ublituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia.; Blood advances. 2023 Jan 23.
• 1. Andritsos LA
  2. Anghelina M
  3. Neal J
  4. Blachly JS
  5. Mathur P
  6. Lele O
  7. Dearden C
  8. Iyengar S
  9. Cross M
  10. Zent CS
  11. Rogers KA
  12. Epperla N
  13. Lozanski G
  14. Oakes CC
  15. Kraut E
  16. Ruppert AS
  17. Zhao Q
  18. Bhat SA
  19. Forconi F
  20. Banerji V
  21. Handunnetti S
  22. Tam CS
  23. Seymour JF
  24. Else M
  25. Kreitman RJ
  26. Saven A
  27. Call T
  28. Parikh SA
  29. Ravandi F
  30. Johnston JB
  31. Tiacci E
  32. Troussard X
  33. Tallman MS
  34. Dietrich S
  35. Tadmor T
  36. Gozzetti A
  37. Zinzani PL
  38. Robak T
  39. Quest G
  40. Demeter J
  41. Rai K
  42. Fernandez SA
  43. Grever M
  Development of a distributed international patient data registry for hairy cell leukemia.; Leukemia & lymphoma. 2022 Sep 07.
• 1. Anghelina M
  2. Naughton MJ
  3. Zhao Q
  4. Ruppert AS
  5. Neal J
  6. Rogers KA
  7. Blachly JS
  8. Lozanski G
  9. Bhat SA
  10. Kraut E
  11. Epperla N
  12. Mathur P
  13. Zent CS
  14. Banerji V
  15. Dearden C
  16. Hutchinson T
  17. Grever M
  18. Andritsos LA
  Corrigendum to "Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemia" [Leuk. Res. 120 (2022) 106919].; Leukemia research. 2022 Sep 02.
• 1. Anghelina M
  2. Naughton MJ
  3. Zhao Q
  4. Ruppert AS
  5. Neal J
  6. Rogers KA
  7. Blachly JS
  8. Lozanski G
  9. Bhat SA
  10. Kraut E
  11. Epperla N
  12. Mathur P
  13. Zent CS
  14. Banerji V
  15. Dearden C
  16. Hutchinson T
  17. Grever M
  18. Andritsos LA
  Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemia.; Leukemia research; Vol 120, pp. 106919. 2022 Jul 18.
• 1. Nkosi D
  2. Zent CS
  3. El Hussein S
  Persistent polyclonal B-cell lymphocytosis: Illustration of the great mimicker of low-grade B-cell lymphoma.; EJHaem; Vol 3(2), pp. 553-554. 2022 Apr 19.
• 1. Pinney JJ
  2. Blick-Nitko SK
  3. Baran AM
  4. Peterson DR
  5. Whitehead HE
  6. Izumi R
  7. Munugalavadla V
  8. Van DerMeid KR
  9. Barr PM
  10. Zent CS
  11. Elliott MR
  12. Chu CC
  The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact.; Haematologica. 2022 Feb 17.
• 1. Ravandi F
  2. Kreitman RJ
  3. Tiacci E
  4. Andritsos L
  5. Banerji V
  6. Barrientos JC
  7. Bhat SA
  8. Blachly JS
  9. Broccoli A
  10. Call T
  11. Chihara D
  12. Dearden C
  13. Demeter J
  14. Dietrich S
  15. Else M
  16. Epperla N
  17. Falini B
  18. Forconi F
  19. Gladstone DE
  20. Gozzetti A
  21. Iyengar S
  22. Johnston JB
  23. Jorgensen J
  24. Juliusson G
  25. Lauria F
  26. Lozanski G
  27. Parikh SA
  28. Park JH
  29. Polliack A
  30. Quest G
  31. Robak T
  32. Rogers KA
  33. Saven A
  34. Seymour JF
  35. Tadmor T
  36. Tallman MS
  37. Tam CS
  38. Thompson PA
  39. Troussard X
  40. Zent CS
  41. Zenz T
  42. Zinzani PL
  43. Wörmann B
  44. Rai K
  45. Grever M
  Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia.; Blood cancer journal; Vol 12(12), pp. 165. 2022 Jan 13.
• 1. Zent CS
  Ibrutinib Restores Tumor Specific Adaptive Immunity in Chronic Lymphocytic Leukemia.; Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Jun 09.
• 1. Grever M
  2. Andritsos L
  3. Banerji V
  4. Barrientos JC
  5. Bhat S
  6. Blachly JS
  7. Call T
  8. Cross M
  9. Dearden C
  10. Demeter J
  11. Dietrich S
  12. Falini B
  13. Forconi F
  14. Gladstone DE
  15. Gozzetti A
  16. Iyengar S
  17. Johnston JB
  18. Juliusson G
  19. Kraut E
  20. Kreitman RJ
  21. Lauria F
  22. Lozanski G
  23. Parikh SA
  24. Park J
  25. Polliack A
  26. Ravandi F
  27. Robak T
  28. Rogers KA
  29. Saven A
  30. Seymour JF
  31. Tadmor T
  32. Tallman MS
  33. Tam CS
  34. Tiacci E
  35. Troussard X
  36. Zent C
  37. Zenz T
  38. Zinzani PL
  39. Wörmann B
  Hairy cell leukemia and COVID-19 adaptation of treatment guidelines.; Leukemia. 2021 May 04.
• 1. Moore JE
  2. Delibert K
  3. Baran AM
  4. Evans AG
  5. Liesveld JL
  6. Zent CS
  Targeted therapy for treatment of patients with classical hairy cell leukemia.; Leukemia research; Vol 102. 2021 Feb 04.
• 1. Zent CS
  2. Ross DM
  Changing of the guard: Leukemia Research 2021.; Leukemia research. 2021 Jan 13.
• 1. Lipof JJ
  2. Huselton EJ
  3. Zent CS
  4. Evans A
  5. Zhang B
  6. Rothberg PG
  7. Bennett JM
  A Case of Acute Eosinophilic Leukemia with a Novel PHF6 Mutation.; Case reports in hematology; Vol 2021. 2021.
• 1. Zent CS
  2. Pinney JJ
  3. Chu CC
  4. Elliott MR
  Complement Activation in the Treatment of B-Cell Malignancies.; Antibodies (Basel, Switzerland); Vol 9(4). 2020 Dec 01.
• 1. Zent CS
  2. Brady MT
  3. Delage C
  4. Strawderman M
  5. Laniewski N
  6. Contant PN
  7. Kanagaiah P
  8. Sangster MY
  9. Barr PM
  10. Chu CC
  11. Topham DJ
  12. Friedberg JW
  Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma.; Leukemia. 2020 Oct 30.
• 1. Rodgers TD
  2. Williams AM
  3. Baran A
  4. Reagan PM
  5. Casulo C
  6. Zent CS
  7. Evans A
  8. Friedberg JW
  9. Barr PM
  Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma.; Leukemia & lymphoma. 2020 Oct 25.
• 1. Pinney JJ
  2. Rivera-Escalera F
  3. Chu CC
  4. Whitehead HE
  5. VanDerMeid K
  6. Nelson AM
  7. Barbeau MC
  8. Zent CS
  9. Elliott MR
  Macrophage hypophagia as a mechanism of innate immune exhaustion in mAb-induced cell clearance.; Blood. 2020 Jun 17.
• 1. Meacham PJ
  2. Williams AM
  3. Strawderman M
  4. Baran AM
  5. Archibald WJ
  6. Wallace DS
  7. Tschernia NP
  8. Burack WR
  9. Barr PM
  10. Zent CS
  Additional B-cell malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL).; Leukemia & lymphoma. 2020 Mar 16.
• 1. Williams AM
  2. van Wijngaarden E
  3. Seplaki CL
  4. Heckler CE
  5. Weber MT
  6. Barr PM
  7. Zent CS
  8. Janelsins MC
  Cognitive function in patients with chronic lymphocytic leukemia: a cross-sectional study examining effects of disease and treatment.; Leukemia & lymphoma. 2020 Mar 09.
• 1. Chu CC
  2. Pinney JJ
  3. Whitehead HE
  4. Rivera-Escalera F
  5. VanDerMeid KR
  6. Zent CS
  7. Elliott MR
  High-resolution quantitation of discrete phagocytic events by live cell time-lapse high-content microscopy imaging.; Journal of cell science. 2020 Jan 31.
• 1. Moore J
  2. Baran AM
  3. Meacham PJ
  4. Evans AG
  5. Barr PM
  6. Zent CS
  Initial treatment of B-cell Prolymphocytic Leukemia with Ibrutinib.; American journal of hematology. 2020 Jan 17.
• 1. Parikh SA
  2. Meacham PJ
  3. Zent CS
  4. Evans AG
  Multiple B cell malignancies in patients with chronic lymphocytic leukemia: epidemiology, pathology, and clinical implications.; Leukemia & lymphoma. 2020 Jan 11.
• 1. Chu CC
  2. Pinney JJ
  3. Whitehead HE
  4. Rivera-Escalera F
  5. VanDerMeid KR
  6. Zent CS
  7. Elliott MR
  High-resolution quantitation of discrete phagocytic events by live cell time-lapse high-content microscopy imaging.; Journal of cell science. 2020 Jan 01.
• 1. Rodgers TD
  2. Baran A
  3. Reagan PM
  4. Casulo C
  5. Zent C
  6. Evans A
  7. Burack R
  8. Williams AM
  9. Friedberg JW
  10. Barr PM
  Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma.; British journal of haematology. 2019 Dec 17.
• 1. Williams AM
  2. Baran AM
  3. Schaffer M
  4. Bushart J
  5. Rich L
  6. Moore J
  7. Barr PM
  8. Zent CS
  Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy.; American journal of hematology. 2019 Oct 17.
• 1. Oostindie SC
  2. van der Horst HJ
  3. Lindorfer MA
  4. Cook EM
  5. Tupitza JC
  6. Zent CS
  7. Burack R
  8. VanDerMeid KR
  9. Strumane K
  10. Chamuleau MED
  11. Mutis T
  12. de Jong RN
  13. Schuurman J
  14. Breij ECW
  15. Beurskens FJ
  16. Parren PWHI
  17. Taylor RP
  CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.; Haematologica. 2019 Feb 21.
• 1. Williams AM
  2. Baran AM
  3. Casulo C
  4. Reagan P
  5. Friedberg JW
  6. Helber M
  7. Moore J
  8. Baloga E
  9. Zent CS
  10. Barr PM
  Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience.; Clinical lymphoma, myeloma & leukemia. 2018 Oct 13.
• 1. Musilova K
  2. Devan J
  3. Cerna K
  4. Seda V
  5. Pavlasova G
  6. Sharma S
  7. Oppelt J
  8. Pytlik R
  9. Prochazka V
  10. Prouzova Z
  11. Trbusek M
  12. Zlamalikova L
  13. Liskova K
  14. Kruzova L
  15. Jarosova M
  16. Mareckova A
  17. Kornauth C
  18. Simonitsch-Klupp I
  19. Schiefer AI
  20. Merkel O
  21. Mocikova H
  22. Burda P
  23. Machova Polakova K
  24. Kren L
  25. Mayer J
  26. Zent CS
  27. Trneny M
  28. Evans AG
  29. Janikova A
  30. Mraz M
  miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels.; Blood. 2018 Sep 13.
• 1. Mato AR
  2. Roeker LE
  3. Allan JN
  4. Pagel JM
  5. Brander DM
  6. Hill BT
  7. Cheson BD
  8. Furman RR
  9. Lamanna N
  10. Tam CS
  11. Handunnetti S
  12. Jacobs R
  13. Lansigan F
  14. Bhavsar E
  15. Barr PM
  16. Shadman M
  17. Skarbnik AP
  18. Goy A
  19. Beach DF
  20. Svoboda J
  21. Pu JJ
  22. Sehgal AR
  23. Zent CS
  24. Tuncer HH
  25. Schuster SJ
  26. Pickens PV
  27. Shah NN
  28. Rhodes J
  29. Ujjani CS
  30. Nabhan C
  Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.; American journal of hematology. 2018 Aug 21.
• 1. VanDerMeid KR
  2. Elliott MR
  3. Baran AM
  4. Barr PM
  5. Chu CC
  6. Zent CS
  Cellular Cytotoxicity of Next Generation CD20 Monoclonal Antibodies.; Cancer immunology research. 2018 Aug 08.
• 1. Archibald WJ
  2. Meacham PJ
  3. Williams AM
  4. Baran AM
  5. Victor AI
  6. Barr PM
  7. Sahasrahbudhe DM
  8. Zent CS
  Management of melanoma in patients with chronic lymphocytic leukemia.; Leukemia research; Vol 71. 2018 Jul 06.
• 1. Mato AR
  2. Thompson M
  3. Allan JN
  4. Brander DM
  5. Pagel JM
  6. Ujjani CS
  7. Hill BT
  8. Lamanna N
  9. Lansigan F
  10. Jacobs R
  11. Shadman M
  12. Skarbnik AP
  13. Pu JJ
  14. Barr PM
  15. Sehgal AR
  16. Cheson BD
  17. Zent CS
  18. Tuncer HH
  19. Schuster SJ
  20. Pickens PV
  21. Shah NN
  22. Goy A
  23. Winter AM
  24. Garcia C
  25. Kennard K
  26. Isaac K
  27. Dorsey C
  28. Gashonia LM
  29. Singavi AK
  30. Roeker LE
  31. Zelenetz A
  32. Williams A
  33. Howlett C
  34. Weissbrot H
  35. Ali N
  36. Khajavian S
  37. Sitlinger A
  38. Tranchito E
  39. Rhodes J
  40. Felsenfeld J
  41. Bailey N
  42. Patel B
  43. Burns TF
  44. Yacur M
  45. Malhotra M
  46. Svoboda J
  47. Furman RR
  48. Nabhan C
  Real world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.; Haematologica. 2018 Jun 07.
• 1. Mato AR
  2. Nabhan C
  3. Thompson MC
  4. Lamanna N
  5. Brander DM
  6. Hill B
  7. Howlett C
  8. Skarbnik A
  9. Cheson BD
  10. Zent C
  11. Pu J
  12. Kiselev P
  13. Goy A
  14. Claxton D
  15. Isaack K
  16. Kennard KH
  17. Timlin C
  18. Landsburg D
  19. Winter A
  20. Nasta SD
  21. Bachow SH
  22. Schuster SJ
  23. Dorsey C
  24. Svoboda J
  25. Barr P
  26. Ujjani CS
  Toxicities and outcomes of 621 ibrutinib-treated chronic lymphocytic leukemia patients in the United States: a real-world analysis.; Haematologica. 2018 Feb 01.
• 1. Taylor RP
  2. Lindorfer MA
  3. Cook EM
  4. Beurskens FJ
  5. Schuurman J
  6. Parren PWHI
  7. Zent CS
  8. VanDerMeid KR
  9. Burack R
  10. Mizuno M
  11. Morgan BP
  Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9.; Clinical immunology (Orlando, Fla.); Vol 181. 2017 Aug.
• 1. Williams AM
  2. Baran AM
  3. Meacham PJ
  4. Feldman MM
  5. Valencia HE
  6. Newsom-Stewart C
  7. Gupta N
  8. Janelsins MC
  9. Barr PM
  10. Zent CS
  Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies.; Leukemia & lymphoma. 2017 Jul 11.
• 1. Murphy EJ
  2. Neuberg DS
  3. Rassenti LZ
  4. Hayes G
  5. Redd R
  6. Emson C
  7. Li K
  8. Brown JR
  9. Wierda WG
  10. Turner S
  11. Greaves AW
  12. Zent CS
  13. Byrd JC
  14. McConnel C
  15. Barrientos J
  16. Kay N
  17. Hellerstein MK
  18. Chiorazzi N
  19. Kipps TJ
  20. Rai KR
  Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia.; Leukemia; Vol 31(6). 2017 Jun.
• 1. Helber MJ
  2. Moore JE
  3. Williams AM
  4. Meacham PJ
  5. Rothberg PG
  6. Zent CS
  Ibrutinib Therapy for Lymphoplasmacytic Lymphoma.; American journal of hematology. 2017 May 24.
• 1. Mato AR
  2. Hill BT
  3. Lamanna N
  4. Barr PM
  5. Ujjani CS
  6. Brander DM
  7. Howlett C
  8. Skarbnik AP
  9. Cheson BD
  10. Zent CS
  11. Pu JJ
  12. Kiselev P
  13. Foon K
  14. Lenhart J
  15. Henick Bachow S
  16. Winter AM
  17. Cruz AL
  18. Claxton DF
  19. Goy A
  20. Daniel C
  21. Isaac K
  22. Kennard KH
  23. Timlin C
  24. Fanning M
  25. Gashonia L
  26. Yacur M
  27. Svoboda J
  28. Schuster SJ
  29. Nabhan C
  Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.; Annals of oncology : official journal of the European Society for Medical Oncology; Vol 28(5). 2017 May 01.
• 1. Grever MR
  2. Abdel-Wahab O
  3. Andritsos LA
  4. Banerji V
  5. Barrientos J
  6. Blachly JS
  7. Call TG
  8. Catovsky D
  9. Dearden C
  10. Demeter J
  11. Else M
  12. Forconi F
  13. Gozzetti A
  14. Ho AD
  15. Johnston JB
  16. Jones J
  17. Juliusson G
  18. Kraut E
  19. Kreitman RJ
  20. Larratt L
  21. Lauria F
  22. Lozanski G
  23. Montserrat E
  24. Parikh SA
  25. Park JH
  26. Polliack A
  27. Quest GR
  28. Rai KR
  29. Ravandi F
  30. Robak T
  31. Saven A
  32. Seymour JF
  33. Tadmor T
  34. Tallman MS
  35. Tam C
  36. Tiacci E
  37. Troussard X
  38. Zent CS
  39. Zenz T
  40. Zinzani PL
  41. Falini B
  Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.; Blood; Vol 129(5). 2017 Feb 02.
• 1. Zent CS
  2. Elliott MR
  Maxed out macs: physiologic cell clearance as a function of macrophage phagocytic capacity.; The FEBS journal. 2016 Nov 14.
• 1. Williams AM
  2. Zent CS
  3. Janelsins MC
  What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research.; British journal of haematology; Vol 174(6). 2016 Sep.
• 1. Cook EM
  2. Lindorfer MA
  3. van der Horst H
  4. Oostindie S
  5. Beurskens FJ
  6. Schuurman J
  7. Zent CS
  8. Burack R
  9. Parren PW
  10. Taylor RP
  Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.; Journal of immunology (Baltimore, Md. : 1950); Vol 197(5). 2016 Sep 01.
• 1. Zent CS
  2. Bowen DA
  3. Conte MJ
  4. LaPlant BR
  5. Call TG
  Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study.; Leukemia & lymphoma; Vol 57(7). 2016 Jul.
• 1. Zent CS
  Chronic lymphocytic leukemia and proteomics: protein profiles and links with disease progression still need validation.; Leukemia & lymphoma; Vol 57(5). 2016 May.
• 1. Zent CS
  2. Victoria Wang X
  3. Ketterling RP
  4. Hanson CA
  5. Libby EN
  6. Barrientos JC
  7. Call TG
  8. Chang JE
  9. Liu JJ
  10. Calvo AR
  11. Lazarus HM
  12. Rowe JM
  13. Luger SM
  14. Litzow MR
  15. Tallman MS
  A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908).; American journal of hematology; Vol 91(3). 2016 Mar.
• 1. Lindorfer MA
  2. Cook EM
  3. Tupitza JC
  4. Zent CS
  5. Burack R
  6. de Jong RN
  7. Beurskens FJ
  8. Schuurman J
  9. Parren PW
  10. Taylor RP
  Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells.; Molecular immunology; Vol 70. 2016 Feb.
• 1. Zent CS
  CLL: an acquired immunodeficiency disease.; Blood; Vol 128(15). 2016 Jan 13.
• 1. Mato AR
  2. Nabhan C
  3. Barr PM
  4. Ujjani CS
  5. Hill BT
  6. Lamanna N
  7. Skarbnik AP
  8. Howlett C
  9. Pu JJ
  10. Sehgal AR
  11. Strelec LE
  12. Vandegrift A
  13. Fitzpatrick DM
  14. Zent CS
  15. Feldman T
  16. Goy A
  17. Claxton DF
  18. Bachow SH
  19. Kaur G
  20. Svoboda J
  21. Nasta SD
  22. Porter D
  23. Landsburg DJ
  24. Schuster SJ
  25. Cheson BD
  26. Kiselev P
  27. Evens AM
  Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.; Blood; Vol 128(18). 2016 Jan 03.
• 1. Church AK
  2. VanDerMeid KR
  3. Baig NA
  4. Baran AM
  5. Witzig TE
  6. Nowakowski GS
  7. Zent CS
  Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages.; Clinical and experimental immunology; Vol 183(1). 2016 Jan.
• 1. Bowen DA
  2. Rabe KG
  3. Schwager SM
  4. Slager SL
  5. Call TG
  6. Viswanatha DS
  7. Zent CS
  Infectious lymphadenitis in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: a rare, but important, complication.; Leukemia & lymphoma; Vol 56(2). 2015 Feb.
• 1. Zent CS
  2. Call TG
  3. Bowen DA
  4. Conte MJ
  5. LaPlant BR
  6. Witzig TE
  7. Ansell SM
  8. Weiner GJ
  Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates.; Leukemia & lymphoma; Vol 56(8). 2015.
• 1. Stilgenbauer S
  2. Furman RR
  3. Zent CS
  Management of chronic lymphocytic leukemia.; American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting. 2015.
• 1. Zent CS
  2. Burack WR
  Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1, SF3B1, and TP53.; Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program; Vol 2014(1). 2014 Dec 5.
• 1. Barr PM
  2. Zent CS
  Infection in chronic lymphocytic leukemia: parsimony has its limits.; Leukemia & lymphoma; Vol 55(12). 2014 Dec.
• 1. Barr PM
  2. Zent CS
  The ABC of CLL: Etiology of cytopenias is important in staging and management; Leuk Lymphoma; Vol 55, pp. 12-19. 2014 Jan 01.
• 1. Conte MJ
  2. Bowen DA
  3. Wiseman GA
  4. Rabe KG
  5. Slager SL
  6. Schwager SM
  7. Call TG
  8. Viswanatha DS
  9. Zent CS
  Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.; Leukemia & lymphoma; Vol 55(9). 2014 Sep.
• 1. Call TG
  2. Norman AD
  3. Hanson CA
  4. Achenbach SJ
  5. Kay NE
  6. Zent CS
  7. Ding W
  8. Cerhan JR
  9. Rabe KG
  10. Vachon CM
  11. Hallberg EJ
  12. Shanafelt TD
  13. Slager SL
  Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines.; Cancer; Vol 120(13). 2014 Jul 01.
• 1. Zent CS
  2. Taylor RP
  3. Lindorfer MA
  4. Beum PV
  5. LaPlant B
  6. Wu W
  7. Call TG
  8. Bowen DA
  9. Conte MJ
  10. Frederick LA
  11. Link BK
  12. Blackwell SE
  13. Veeramani S
  14. Baig NA
  15. Viswanatha DS
  16. Weiner GJ
  17. Witzig TE
  Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.; American journal of hematology; Vol 89(7). 2014 Jul.
• 1. Slager SL
  2. Zent CS
  Genetic risk of chronic lymphocytic leukemia: a tale of two cities.; Leukemia & lymphoma; Vol 55(4). 2014 Apr.
• 1. Baig NA
  2. Taylor RP
  3. Lindorfer MA
  4. Church AK
  5. LaPlant BR
  6. Pettinger AM
  7. Shanafelt TD
  8. Nowakowski GS
  9. Zent CS
  Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.; Journal of immunology (Baltimore, Md. : 1950); Vol 192(4). 2014 Feb 15.
• 1. Shanafelt T
  2. Lanasa MC
  3. Call TG
  4. Beaven AW
  5. Leis JF
  6. LaPlant B
  7. Bowen D
  8. Conte M
  9. Jelinek DF
  10. Hanson CA
  11. Kay NE
  12. Zent CS
  Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).; Cancer; Vol 119(21). 2013 Nov 01.
• 1. Greipp PT
  2. Smoley SA
  3. Viswanatha DS
  4. Frederick LS
  5. Rabe KG
  6. Sharma RG
  7. Slager SL
  8. Van Dyke DL
  9. Shanafelt TD
  10. Tschumper RC
  11. Zent CS
  Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis; Br J Haematol; Vol 163(3), pp. 326-33. 2013 Jan 01.
• 1. Charbonneau B
  2. Wang AH
  3. Maurer MJ
  4. Asmann YW
  5. Zent CS
  6. Link BK
  7. Ansell SM
  8. Weiner GJ
  9. Ozsan N
  10. Feldman AL
  11. Witzig TE
  12. Cunningham JM
  13. Dogan A
  14. Habermann TM
  15. Slager SL
  16. Novak AJ
  17. Cerhan JR
  CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis.; Cancer immunology, immunotherapy : CII; Vol 62(9). 2013 Sep.
• 1. Parikh SA
  2. Rabe KG
  3. Call TG
  4. Zent CS
  5. Habermann TM
  6. Ding W
  7. Leis JF
  8. Schwager SM
  9. Hanson CA
  10. Macon WR
  11. Kay NE
  12. Slager SL
  13. Shanafelt TD
  Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients.; British journal of haematology; Vol 162(6). 2013 Sep.
• 1. Witzig TE
  2. Wiseman GA
  3. Maurer MJ
  4. Habermann TM
  5. Micallef IN
  6. Nowakowski GS
  7. Ansell SM
  8. Colgan JP
  9. Inwards DJ
  10. Porrata LF
  11. Link BK
  12. Zent CS
  13. Johnston PB
  14. Shanafelt TD
  15. Allmer C
  16. Asmann YW
  17. Gupta M
  18. Ballas ZK
  19. Smith BJ
  20. Weiner GJ
  A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.; American journal of hematology; Vol 88(7). 2013 Jul.
• 1. Gonsalves WI
  2. Zent CS
  3. Pulido JS
  4. Patnaik MM
  Visual loss in early-stage chronic lymphocytic leukemia.; Journal of clinical oncology : official journal of the American Society of Clinical Oncology; Vol 31(17). 2013 Jun 10.
• 1. Shanafelt TD
  2. Ramsay AG
  3. Zent CS
  4. Leis JF
  5. Tun HW
  6. Call TG
  7. LaPlant B
  8. Bowen D
  9. Pettinger A
  10. Jelinek DF
  11. Hanson CA
  12. Kay NE
  Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).; Blood; Vol 121(20). 2013 May 16.
• 1. Kourelis TV
  2. Gertz M
  3. Zent C
  4. Lacy M
  5. Kyle R
  6. Kapoor P
  7. Zeldenrust S
  8. Buadi F
  9. Witzig T
  10. Hayman S
  11. Lust J
  12. Russell S
  13. Lin Y
  14. Rajkumar VS
  15. Kumar S
  16. Leung N
  17. Dingli D
  18. Dispenzieri A
  Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma.; American journal of hematology; Vol 88(5). 2013 May.
• 1. Zent CS
  2. Wu W
  3. Bowen DA
  4. Hanson CA
  5. Pettinger AM
  6. Shanafelt TD
  7. Kay NE
  8. Leis JF
  9. Call TG
  Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphpocytic leukemia with alemtuzumab and rituximab; Leuk Lymphoma; Vol 54(3), pp. 476-82. 2013 Jan 01.
• 1. Shanafelt TD
  2. Call TG
  3. Zent CS
  4. Leis JF
  5. LaPlant B
  6. Bowen DA
  7. Roos M
  8. Laumann K
  9. Ghosh AK
  10. Lesnick C
  11. Lee MJ
  12. Yang CS
  13. Jelinek DF
  14. Erlichman C
  15. Kay NE
  Phase 2 trial of daily, oral polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphpocytic leukemia; Cancer; Vol 119(2), pp. 363-70. 2013 Jan 01.
• 1. Baig NA
  2. Taylor RP
  3. Lindorfer MA
  4. Church AK
  5. LaPlant B
  6. Pavey ES
  7. Nowakowski GS
  8. Zent CS
  Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement; Leuk Lymphoma; Vol 53(11), pp. 2218-27. 2012 Jan 01.
• 1. Charbonneau B
  2. Maurer MJ
  3. Fredericksen ZS
  4. Zent CS
  5. Link BK
  6. Novak AJ
  7. Ansell SM
  8. WeinerGJ WA
  9. Witzig TE
  10. Dogan A
  11. Slager SL
  12. Habermann TM
  13. Cerhan JR
  Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma; Am J Hematol; Vol 87(9), pp. 880-5. 2012 Jan 01.
• 1. Lindorfer MA
  2. Wiestner A
  3. Zent CS
  4. Taylor RP
  Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?; Oncoimmunology; Vol 1(6), pp. 959-61. 2012 Jan 01.
• 1. Taylor RP
  2. Lindorfer MA
  3. Zent CS
  Anti-CD20 antibody therapy for B-cell lymphomas; N Engl J Med; Vol 367(9), pp. 876-7. 2012 Jan 01.
• 1. Zent CS
  Improving quality of life in chronic lymphocytic leukemia; Leuk Lymphoma; Vol 53(7), pp. 1247-8. 2012 Jan 01.
• 1. Shanafelt TD
  2. Kay NE
  3. Rabe KG
  4. Inwards DJ
  5. Zent CS
  6. Leis JF
  7. Schwager SM
  8. Thompson CA
  9. Bowen DA
  10. Witzig TE
  11. Slager SL
  12. Call TG
  Hematologist/oncologist disease-specific expertise and survival: lessions from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); Cancer; Vol 118(7), pp. 1827-37. 2012 Jan 01.
• 1. Gustafson MP
  2. Abraham RS
  3. Lin Y
  4. Wu W
  5. Gastineau DA
  6. Zent CS
  7. Dietz AB
  Association of an increased frequency of CD14+ HLA-DR lo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL); Br J Haematol; Vol 156(5), pp. 674-6. 2012 Jan 01.
• 1. Shanafelt TD
  2. Kay NE
  3. Rabe KG
  4. Call TG
  5. Zent CS
  6. Schwager SM
  7. Leis JF
  8. Jelinek DF
  9. Slager SL
  10. Hanson CA
  Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population.; Leukemia; Vol 26(2). 2012 Feb.
• 1. Zent CS
  2. Smith BJ
  3. Ballas ZK
  4. Wooldridge JE
  5. Link BK
  6. Call TG
  7. Shanafelt TD
  8. Bowen DA
  9. Kay NE
  10. Witzig TE
  11. Weinier GJ
  Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia; Leuk Lymphoma; Vol 53(2), pp. 211-7. 2012 Jan 01.
• 1. Shanafelt TD
  2. Kay NE
  3. Rabe KG
  4. Call TG
  5. Zent CS
  6. Schwager SM
  7. Leis JF
  8. Jelinek DF
  9. Slager SL
  10. Hanson CA
  Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population; Leukemia; Vol 26(2), pp. 373-6. 2012 Jan 01.
• 1. Zent CS
  Multi-parameter prognostication in chronic lymphocytic leukemia; Leuk Lymphoma; Vol 52(10), pp. 1823-4. 2011 Jan 01.
• 1. Mraz M
  2. Zent CS
  3. Church AK
  4. Jelinek DF
  5. Wu X
  Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alpha-4-beta-1 (VLA-4) with natalizumab can overcome this resistance; Br J Haematol; Vol 155(1), pp. 53-64. 2011 Jan 01.
• 1. Maurer MJ
  2. Cerhan JR
  3. Katzmann JA
  4. Link BK
  5. Allmer C
  6. Zent CS
  7. Call TG
  8. Rabe KG
  9. Hanson CA
  10. Kay NE
  11. Slager SL
  12. Witzig TE
  13. Shanafelt TD
  Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia; Blood; Vol 118(10), pp. 2821-6. 2011 Jan 01.
• 1. Zent CS
  2. Kay NE
  Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach; Leuk Lymphoma; Vol 52(8), pp. 1425-34. 2011 Jan 01.
• 1. Chen D
  2. Kettering RP
  3. Hanson CA
  4. Colgan JP
  5. Zent CS
  6. Viswanatha DS
  A case of hairy cell leukemia with CCND1-IGH translocation: indolent non-nodal mantle cell lymphoma revisited; Am J Surg Pathol; Vol 35(7), pp. 1080-4. 2011 Jan 01.
• 1. Zent CS
  2. Polliack A
  3. Tadmor T
  FISHing for answers in proliferation centers of chronic lymphocytic leukemia lymph nodes; Leuk Lymphoma; Vol 52(6), pp. 946-7. 2011 Jan 01.
• 1. Shanafelt TD
  2. Drake MT
  3. Maurer MJ
  4. Allmer C
  5. Rabe KG
  6. Slager SL
  7. Weiner GH
  8. Call TG
  9. Link BK
  10. Zent CS
  11. Kay NE
  12. Hanson CA
  13. Witzig TE
  14. Cerhan JR
  Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia; Blood; Vol 117(5), pp. 1492-8. 2011 Jan 01.
• 1. Gutierrez A
  2. Arendt BK
  3. Tschumper RC
  4. Kay NE
  5. Zent CS
  6. Jelinek DF
  Differentiation of chronic lymphocytic leukemia B-cells into immunoglobulin secreting cells decreases LEF-1 expression; PLoS One; Vol 6(10). 2011 Jan 01.
• 1. Shanafelt T
  2. Zent C
  3. Byrd J
  4. Erlichman C
  5. LaPlant B
  6. Ghosh A
  7. Call T
  8. Villalona-Calero M
  9. Jelinek D
  10. Bowen D
  11. Laumann K
  12. Wu W
  13. Hanson C
  14. Kay N
  Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia; Leuk Lymphoma; Vol 51(12), pp. 2222-9. 2010 Jan 01.
• 1. Shanafelt TD
  2. Rabe KG
  3. Kay NE
  4. Zent CS
  5. Jelinek DF
  6. Reinalda MS
  7. Schwager SM
  8. Bowen DA
  9. Slager SL
  10. Hanson CA
  11. Call TG
  Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia.; Cancer; Vol 116(20). 2010 Oct 15.
• 1. Shanafelt TD
  2. Rabe KG
  3. Kay NE
  4. Zent CS
  5. Jelinek DF
  6. Reinalda MS
  7. Schwager SM
  8. Bowen DA
  9. Slager SL
  10. Hanson CA
  11. Call TG
  Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia; Cancer; Vol 116(20), pp. 4777-87. 2010 Jan 01.
• 1. Zent CS
  Cell-mediated immunity in chronic lymphocytic leukemia; Leuk Lymphoma; Vol 51(10), pp. 1775-6. 2010 Jan 01.
• 1. Jevremovic D
  2. Dronca RS
  3. Morice WG
  4. McPhail ED
  5. Kurtin PG
  6. Zent CS
  CD5+ B-cell lymphoproliferative disorders: Beyond chronic lymphocytic leukemia and mantle cell lymphoma; Leuk Res; Vol 34(9), pp. 1235-8. 2010 Jan 01.
• 1. Shanafelt TD
  2. Rabe KG
  3. Kay NE
  4. Zent CS
  5. Call TG
  6. Slager SL
  7. Bowen DA
  8. Schwager SM
  9. Nowakowski GS
  Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chornic lymphocytic leukemia; Leuk Lymphoma; Vol 51(7), pp. 1233-40. 2010 Jan 01.
• 1. Zent CS
  Chronic Lymphocytic Leukemia in the Elderly: Who Should be Treated?; Am Soc Clin Oncol Ed. 2010 Jan 01.
• 1. Bauer PR
  2. Zent CS
  3. Aubry MC
  4. Ryu JH
  Recurrent fevers, cough, and pulmonary opacities in a middle-aged man; Chest; Vol 137(6), pp. 1465-9. 2010 Jan 01.
• 1. Zent CS
  Time to test CLL p53 function; Blood; Vol 115(21), pp. 4154-5. 2010 Jan 01.
• 1. Zent CS
  2. LaPlant BR
  3. Johnston PB
  4. Call TG
  5. Habermann TM
  6. Micallef IN
  7. Witzig TE
  The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation; Cancer; Vol 116(9), pp. 2201-7. 2010 Jan 01.
• 1. Kay NE
  2. Wu W
  3. Kabat B
  4. LaPlant B
  5. Lin TS
  6. Byrd JC
  7. Jelinek DF
  8. Grever MR
  9. Zent CS
  10. Call TG
  11. Shanafelt TD
  Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia; Cancer; Vol 116(9), pp. 2180-7. 2010 Jan 01.
• 1. Bowen DA
  2. Call TG
  3. Shanafelt TD
  4. Kay NE
  5. Schwager RM
  6. Reinalda MS
  7. Rabe KG
  8. Slager SL
  9. Zent CS
  Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone; Leuk Lymphoma; Vol 51(4), pp. 620-7. 2010 Jan 01.
• 1. Zent CS
  2. Kay NE
  Autoimmune complications in chronic lymphocytic leukaemia (CLL); Best Pract Res Clin Haematol; Vol 23(1), pp. 47-59. 2010 Jan 01.
• 1. Zent CS
  2. Van Dyke DL
  Detection of recurrent chromosomal defects in chronic lymphocytic leukemia/small lymphocytic lymphoma: innovations and applications; Leuk Lymphoma; Vol 51(2), pp. 186-7. 2010 Jan 01.
• 1. Van Dyke DL
  2. Shanafelt TD
  3. Call TG
  4. Zent CS
  5. Smoley SA
  6. Rabe KG
  7. Schwager SM
  8. Sonbert JC
  9. Slager SL
  10. Kay NE
  A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia; Br J Haematol; Vol 148(4), pp. 544-50. 2010 Jan 01.
• 1. Dronca RS
  2. Jevremovic D
  3. Hanson CA
  4. Rabe KG
  5. Shanafelt TD
  6. Morice WG
  7. Call TG
  8. Kay NE
  9. Collins CS
  10. Schwager SM
  11. Slager SL
  12. Zent CS
  CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity; Cytometry B Clin Cytom; Vol 58(Suppl 1), pp. 35-41. 2010 Jan 01.
• 1. Ding W
  2. Nowakowski GS
  3. Knox TR
  4. Boysen JC
  5. Maas ML
  6. Schwager SM
  7. Wu W
  8. Wellik LE
  9. Dietz AB
  10. Ghosh AK
  11. Secreto CR
  12. Medina KL
  13. Shanafelt TD
  14. Zent CS
  15. Call TG
  16. Kay NE
  Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression; Br J Haematol; Vol 147(4), pp. 471-83. 2009 Jan 01.
• 1. Pardanani A
  2. Tefferi A
  3. Litzow MR
  4. Zent C
  5. Hogan WJ
  6. McClure RF
  7. Viswanatha D
  Chronic myeloid leukemia with p190BCR-ABL: prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis.; Blood; Vol 114(16). 2009 Oct 15.
• 1. Shanafelt TD
  2. Byrd JC
  3. LaPlant B
  4. Zent CS
  5. Call T
  6. Secreto C
  7. Grever MR
  8. Lin TS
  9. Kay NE
  Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia; Br J Haematol; Vol 146(6), pp. 660-4. 2009 Jan 01.
• 1. Shanafelt TD
  2. Call TG
  3. Zent CS
  4. LaPlant B
  5. Bowen DA
  6. Roos M
  7. Secreto CR
  8. Ghosh AK
  9. Kabat BF
  10. Lee MJ
  11. Yang CS
  12. Jelinek DF
  13. Erlichman C
  14. Kay NE
  Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia; J Clin Oncol; Vol 27(23), pp. 3808-14. 2009 Jan 01.
• 1. Shanafelt TD
  2. Kay NE
  3. Rabe KG
  4. Call TG
  5. Zent CS
  6. Maddocks K
  7. Jenkins G
  8. Jelinek DF
  9. Morice WG
  10. Boysen J
  11. Schwager S
  12. Bowen D
  13. Slager SL
  14. Hanson CA
  Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia; J Clin Oncol; Vol 27(24), pp. 3959-63. 2009 Jan 01.
• 1. Zent CS
  2. Ding W
  3. Reinalda MS
  4. Schwager SM
  5. Hoyer JD
  6. Bowen DA
  7. Jelinek DF
  8. Tschumper RC
  9. Call TG
  10. Shanafelt TD
  11. Kay NE
  12. Slager SL
  Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis; Leuk Lymphoma; Vol 50(8), pp. 1261-8. 2009 Jan 01.
• 1. Zent CS
  2. Shanafelt T
  Management of autoimmune cytopenia complicating chronic lymphocytic leukemia; Leuk Lymphoma; Vol 50(6), pp. 863-4. 2009 Jan 01.
• 1. Shanafelt TD
  2. Kay NE
  3. Jenkins G
  4. Call TG
  5. Zent CS
  6. Jelinek DF
  7. Morice WG
  8. Boysen J
  9. Zakko L
  10. Schwager S
  11. Slager SL
  12. Hanson CA
  B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome; Blood; Vol 113(18), pp. 4188-96. 2009 Jan 01.
• 1. Nowakowski GS
  2. Hoyer JD
  3. Shanafelt TD
  4. Zent CS
  5. Call TG
  6. Bone ND
  7. Laplant B
  8. Dewald GW
  9. Tschumper RC
  10. Jelinek DF
  11. Witzig TE
  12. Kay NE
  Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia; J Clin Oncol; Vol 27(11), pp. 1844-9. 2009 Jan 01.
• 1. Shanafelt TD
  2. Bowen DA
  3. Venkat C
  4. Slager SL
  5. Zent CS
  6. Kay NE
  7. Reinalda M
  8. Tun H
  9. Sloan JA
  10. Call TG
  The physician-patient relationship and quality of life: lessons from chronic lymphocytic leukemia; Leuk Res; Vol 33(2), pp. 263-70. 2009 Jan 01.
• 1. Awan FT
  2. Kay NE
  3. Davis ME
  4. Wu W
  5. Geyer SM
  6. Leung N
  7. Jelinek DF
  8. Tschumper RC
  9. Secreto CR
  10. Lin TS
  11. Grever MR
  12. Shanafelt TD
  13. Zent CS
  14. Call TG
  15. Heerema NA
  16. Lozanski G
  17. Byrd JC
  18. Lucas DM
  Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.; Blood; Vol 113(3). 2009 Jan 15.
• 1. Shanafelt TD
  2. Jenkins G
  3. Call TG
  4. Zent CS
  5. Slager S
  6. Bowen DA
  7. Schwager S
  8. Hanson CA
  9. Jelinek DF
  10. Kay NE
  Validation of a new prognostic index for patients with chronic lymphocytic leukemia; Cancer; Vol 115(2), pp. 363-72. 2009 Jan 01.
• 1. Zent CS
  2. Secreto CR
  3. LaPlant BR
  4. Bone ND
  5. Call TG
  6. Shanafelt TD
  7. Jelinek DF
  8. Tschumper RC
  9. Kay NE
  Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab; Leuk Res; Vol 32(12), pp. 1849-56. 2008 Jan 01.
• 1. Zent CS
  2. Call TS
  3. TD TR
  4. Jelinek DF
  5. Bowen DA
  6. Secreto CR
  7. Laplant BR
  8. Kabat BF
  9. Kay NE
  Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab; Cancer; Vol 113(8), pp. 2110-8. 2008 Jan 01.
• 1. Shanafelt TD
  2. Kay NE
  3. Cell TG
  4. Zent CS
  5. Jelinek DF
  6. LaPlant B
  7. Morice WG
  8. Hanson CA
  MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count , greater than or equal to 5 x 10e9/L but a B-cell lymphocyte count less than or equal to 5 x 10e9/L?; Leuk Res; Vol 32(9), pp. 1458-61. 2008 Jan 01.
• 1. Holtan SG
  2. Porrata LF
  3. Colgan JP
  4. Zent CS
  5. Habermann TM
  6. Markovic SN
  mTOR inhibitor monotherapy is insufficient to suppress viremia and disease progression in Epstein-Barr virus-driven lymphoproliferative disorders (EBV-LPD).; American journal of hematology; Vol 83(8). 2008 Aug.
• 1. Hogan WJ
  2. Zent CS
  Stem cell transplant for chronic lymphocytic leukemia/small lymphocytic lymphoma.; Leukemia & lymphoma; Vol 49(5). 2008 May.
• 1. Palmer S
  2. Hanson CA
  3. Zent CS
  4. Porrata LF
  5. Laplant B
  6. Geyer SM
  7. Markovic SN
  8. Call TG
  9. Bowen DA
  10. Jelinek DF
  11. Kay NE
  12. Shanafelt TD
  Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia; Br J Haematol; Vol 141(5), pp. 607-14. 2008 Jan 01.
• 1. Zent CS
  2. Ding W
  3. Schwager SM
  4. Reinalda MS
  5. Hoyer JD
  6. Jelinek DF
  7. Tschumper RC
  8. Bowen DA
  9. Call TG
  10. Shanafelt TD
  11. Kay NE
  12. Slager SL
  The prognostic significant of cytopenia in chronoc lymphocytic leukaemia/small lymphocytic lymphoma; Br J Haematol; Vol 141(5), pp. 615-21. 2008 Jan 01.
• 1. Hogan WJ
  2. Zent CS
  Stem cell transplant for chronic lymphocytic leukemia/small lymphocytic lymphoma; Leuk Lymphoma; Vol 49(5), pp. 835-6. 2008 Jan 01.
• 1. Shanafelt TD
  2. Geyer SM
  3. Bone ND
  4. Tschumper RC
  5. Witzig TE
  6. Nowakowski GS
  7. Zent CS
  8. Call TG
  9. Laplant B
  10. Dewald GW
  11. Jelinek DF
  12. Kay NE
  CD49d expression is an independent predictor of overall survival i npatients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential; Br J Haematol; Vol 140(5), pp. 537-46. 2008 Jan 01.
• 1. Zent CS
  The role of alemtuzumab in the treatment of chronic lymphocytic leukemia.; Leukemia & lymphoma; Vol 49(2). 2008 Feb.
• 1. Thurmes P
  2. Call T
  3. Slager S
  4. Zent C
  5. Jenkins G
  6. Schwager S
  7. Bowen D
  8. Kay NE
  9. Shanafelt T
  Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia; Leuk Lymphoma; Vol 49(1), pp. 49-56. 2008 Jan 01.
• 1. Tschumper RC
  2. Geyer SM
  3. Campbell ME
  4. Kay NE
  5. Shanafelt TD
  6. Zent CS
  7. Nowakowski GS
  8. Call TG
  9. Dewald GW
  10. Jelinek DF
  Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients; J Clin Invest; Vol 118(1), pp. 306-15. 2008 Jan 01.
• 1. Bowen DA
  2. Call TG
  3. Jenkins GD
  4. Zent CS
  5. Schwager SM
  6. Van Dyke DL
  7. Jelinek DF
  8. Kay NE
  9. Shanafelt TD
  Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features; Leuk Lymphoma; Vol 48(12), pp. 2412-7. 2007 Jan 01.
• 1. Browning RL
  2. Geyer SM
  3. Johnson AJ
  4. Jelinek DF
  5. Tschumper RC
  6. Call TG
  7. Shanafelt TD
  8. Zent CS
  9. Bone ND
  10. Dewald GW
  11. Lin TS
  12. Heerema NA
  13. Gever MR
  14. Kay NE
  15. Byrd JC
  16. Lucas DM
  Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia; Leuk Res; Vol 49(1), pp. 49-56. 2007 Jan 01.
• 1. Maddocks-Christianson K
  2. Slager SL
  3. Zent CS
  4. Reinalda M
  5. Call TG
  6. Habermann TM
  7. Bowen DA
  8. Hoyer JD
  9. Schwager S
  10. Jelinek DF
  11. Kay NE
  12. Shanafelt TD
  Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia; Br J Haematol; Vol 139(3), pp. 398-404. 2007 Jan 01.
• 1. Shanafelt TD
  2. Bowen D
  3. Venkat C
  4. Slager SL
  5. Zent CS
  6. Kay NE
  7. Reinalda M
  8. Sloan JA
  9. Call TG
  Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients; Br J Haematol; Vol 139(2), pp. 255-64. 2007 Jan 01.
• 1. Zent CS
  2. Kay NE
  Chronic lymphocytic leukemia: biology and current treatment; Curr Oncol Rep; Vol 9(5), pp. 345-52. 2007 Jan 01.
• 1. Shanafelt TD
  2. Lin T
  3. Geyer SM
  4. Zent CS
  5. Leung N
  6. Kabat B
  7. Bowen D
  8. Grever MR
  9. Byrd JC
  10. Kay NE
  Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia; Cancer; Vol 109(11), pp. 2291-8. 2007 Jan 01.
• 1. Nowakowski GS
  2. Hoyer JD
  3. Shanafelt TD
  4. Geyer SM
  5. LaPlant BR
  6. Call TG
  7. Jelinek DF
  8. Zent CS
  9. Kay NE
  Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: a universally available prognostic test; Mayo Clin Proc; Vol 82(4), pp. 449-53. 2007 Jan 01.
• 1. Ding W
  2. Zent CS
  Diagnosis and management of autoimmune complications of chronic lymphocytic leukemia/small lymphocytic lymphoma; Clin Adv Hematol Oncol; Vol 5(4), pp. 257-61. 2007 Jan 01.
• 1. Rockacy J
  2. Viozzi CF
  3. Zent CS
  Mantle cell lymphoma presenting as a slowly enlarging lesion of the floor of mouth in a healthy 72 year old: report of a case; J Oral Maxillofac Surg; Vol 65(2), pp. 333-7. 2007 Jan 01.
• 1. Kay NE
  2. Geyer SM
  3. Call TG
  4. Shanafelt TD
  5. Zent CS
  6. Jelinek DF
  7. Tschumper R
  8. Bone ND
  9. Dewald GW
  10. Lin TS
  11. Heerema NA
  12. Smith L
  13. Grever MR
  14. Byrd JC
  Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia; Blood; Vol 109(2), pp. 405-11. 2007 Jan 01.
• 1. Zent CS
  2. Polliack A
  Staging chronic lymphocytic leukemia (CLL) for prognosis at diagnosis; Leuk Lymphoma; Vol 47(12), pp. 2433-4. 2006 Jan 01.
• 1. Zent CS
  Chronic B-cell lymphoproliferative disorders: how many diseases?; Leuk Lymphoma; Vol 47(10), pp. 2006-7. 2006 Jan 01.
• 1. Shanafelt TD
  2. Witzig TE
  3. Fink SR
  4. Jenkins RB
  5. Paternoster SF
  6. Smoley SA
  7. Stockero KJ
  8. Nast DM
  9. Flynn HC
  10. Tschumper RC
  11. Geyer S
  12. Zent CS
  13. Call TG
  14. Jelinek DF
  15. Kay NE
  Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia; J Clin Oncol; Vol 24(28), pp. 4634-41. 2006 Jan 01.
• 1. Zent CS
  2. Call TG
  3. Hogan WJ
  4. Shanafelt TD
  5. Kay NE
  Update on risk-stratified management for chronic lymphocytic leukemia; Leuk Lymphoma; Vol 47(9), pp. 1738-46. 2006 Jan 01.
• 1. Shanafelt TD
  2. Byrd JC
  3. Call TG
  4. Zent CS
  5. Kay NE
  Narrative review: initial management for chronic lymphocytic leukemia; Ann Intern Med; Vol 145(6), pp. 435-47. 2006 Jan 01.
• 1. Lee HB
  2. Pulido JS
  3. Buettner H
  4. Salomao D
  5. Zent CS
  6. Link TP
  Intravascular B-cell lymphoma (angiotropic lymphoma) with choroidal involvement; Arch Ophthalmol; Vol 124(9), pp. 1357-9. 2006 Jan 01.
• 1. Zent CS
  Autoimmunity and chronic lymphocytic leukemia; Leuk Lymphoma; Vol 47(8), pp. 1443-4. 2006 Jan 01.
• 1. Nora EH
  2. Hamacher KL
  3. Zent CS
  4. Ghosh AK
  Indolent systemic mastocytosis as the cause of a long history of unexplained hypotensive episodes; South Med J; Vol 99(8), pp. 876-9. 2006 Jan 01.
• 1. Osborn NK
  2. Ustundag Y
  3. Zent CS
  4. Wiesner RH
  5. Rosen CB
  6. Narayanan MK
  Factor XII deficiency acquired by orthotopic liver transplantation: case report and review of the literature; Am J Transplant; Vol 6(7), pp. 1743-5. 2006 Jan 01.
• 1. Fink SR
  2. Smoley SA
  3. Stockero KJ
  4. Paternoster SF
  5. Thorland EC
  6. Van Dyke DL
  7. Shanafelt TD
  8. Zent CS
  9. Call TG
  10. Kay NE
  11. Dewald GW
  Loss of TP53 due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemia; Cancer Genet Cytogenet; Vol 167(2), pp. 177-81. 2006 Jan 01.
• 1. Stockero KJ
  2. Fink SR
  3. Smoley SA
  4. Paternoster SF
  5. Shanafelt TD
  6. Call TG
  7. Zent CS
  8. Van Dyke DL
  9. Kay NE
  10. Dewald GW
  Metaphase cells with normal G-bands have cryptic interstitial deletions in 13q14 detectable by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia; Cancer Genet Cytogenet; Vol 166(2), pp. 152-6. 2006 Jan 01.
• 1. Shanafelt TD
  2. Lee YK
  3. Call TG
  4. Nowakowski GS
  5. Dingli D
  6. Zent CS
  7. Kay NE
  Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies; Leuk Res; Vol 30(6), pp. 707-12. 2005 Jan 01.
• 1. Nowakowski GS
  2. Dewald GW
  3. Hoyer JD
  4. Paternoster SF
  5. Stockero KJ
  6. Fink SR
  7. Smoley SA
  8. Remstein ED
  9. Phyliky RL
  10. Call TG
  11. Shanafelt TD
  12. Kay NE
  13. Zent CS
  Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia; Br J Haematol; Vol 130(1), pp. 36-42. 2005 Jan 01.
• 1. Nowakowski GS
  2. Call TG
  3. Morice WG
  4. Kurtin PJ
  5. Cook RJ
  6. Zent CS
  Clinical significance of monoclonal B cells in cerebrospinal fluid; Cytometry B Clin Cytom; Vol 63(1), pp. 23-7. 2005 Jan 01.
• 1. Kohli M
  2. Zent C
  3. Hutchins LF
  4. Safar M
  5. Dotson P
  6. Mehta P
  The academic hematology-oncology firm: a model for postgraduate cancer education; J Cancer Educ; Vol 19(1), pp. 45-9. 2004 Jan 01.
• 1. Zent CS
  2. Kay NE
  Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia; Curr Oncol Rep; Vol 6(5), pp. 348-54. 2004 Jan 01.
• 1. Zent CS
  2. Chen JB
  3. Kurten RC
  4. Kaushal GP
  5. Lacy HM
  6. Schichman SA
  Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium; Leuk Res; Vol 28(5), pp. 495-507. 2004 Jan 01.
• 1. Kyasa MJ
  2. Hazlett L
  3. Parrish RS
  4. Schichman SA
  5. Zent CS
  Veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have a markedly increased rate of second malignancy, which is the most common cause of death; Leuk Lymphoma; Vol 45(3), pp. 507-13. 2004 Jan 01.
• 1. Zent CS
  2. Kay NE
  Update on monoclonal antibody therapy in chronic lymphocytic leukemia; Clin Adv Hematol Oncol; Vol 2(2), pp. 107-13. 2004 Jan 01.
• 1. Zent CS
  2. Zhan FG
  3. Schichman SA
  4. Bumm K
  5. Lin P
  6. Chen JB
  7. Shaughnessy JD
  The distinct gene expression profiles of chronic lymphocytic leukemia and multiple myeloma suggest different anti-apoptotic mechanisms but predict only some differences in phenotype; Leuk Res; Vol 27(9), pp. 765-74. 2003 Jan 01.
• 1. Kyasa MJ
  2. Parrish RS
  3. Schichman SA
  4. Zent CS
  Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma; Am J Hematol; Vol 74(1), pp. 1-8. 2003 Jan 01.
• 1. Monson T
  2. Schichman SA
  3. Zent CS
  Linezolid-induced pure red blood cell aplasia; Clin Infect Dis; Vol 35(3), pp. 29-31. 2002 Jan 01.
• 1. Kohli M
  2. Fink LM
  3. Spencer JH
  4. Zent CS
  Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer; Blood Coagul Fibrinolysis; Vol 13(1), pp. 1-5. 2002 Jan 01.
• 1. Joseph L
  2. Scott MA
  3. Schichman SA
  4. Zent CS
  Localized herpes simplex lymphadenitis mimicking large-cell (Richter's) transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma; Am J Hematol; Vol 68(4), pp. 287-91. 2001 Jan 01.
• 1. Zent CS
  2. Kyasa MJ
  3. Evans R
  4. Schichman SA
  Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data; Cancer; Vol 92(5), pp. 1325-30. 2001 Jan 01.
• 1. Zent C
  Anemia and chronic disease; US Medicine; Vol 37(5 Suppl), pp. 5-8. 2001 Jan 01.
• 1. Kohli M
  2. Schichman SA
  3. Fink L
  4. Zent CS
  Use of HFE mutation analysis for hereditary hemochromatosis: the need for physician education in the translation of basic science to clinical practice; South Med J; Vol 93(5), pp. 469-71. 2000 Jan 01.
• 1. Govindarajan R
  2. Baxter D
  3. Wilson C
  4. Zent C
  Vancomycin-induced thrombocytopenia.; American journal of hematology; Vol 62(2). 1999 Oct.
• 1. Zent CS
  2. Ratajczak J
  3. Ratajczak MZ
  4. Anastasi J
  5. Hoffman PC
  6. Gewirtz AM
  Relationship between megakaryoctye mass and serum thrombopoietin levels as revealed by a case of cyclic amegakaryocytic thrombocytopenic purpura; Br J Haematol; Vol 105(2), pp. 452-8. 1999 Jan 01.
• 1. Zent CS
  2. Wilson CS
  3. Tricot G
  4. Jagannath S
  5. Siegel D
  6. Desikan KR
  7. Munshi N
  8. Bracy D
  9. Barlogie B
  10. Butch AW
  Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation; Blood; Vol 91(9), pp. 3518-23. 1998 Jan 01.
• 1. Zent C
  2. Rowley JD
  3. Nucifora G
  Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies; Leukemia; Vol 3(11 Suppl), pp. 273-8. 1997 Jan 01.
• 1. Zent CS
  2. Mathieu C
  3. Claxton DF
  4. Zhang DE
  5. Tenen DG
  6. Rowley JD
  7. Nucifora G
  The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoter properties; Proc Natl Acad Sci; Vol 93(3), pp. 1044-8. 1996 Jan 01.
• 1. Zent C
  2. Kim N
  3. Hiebert S
  4. Zhang DE
  5. Tenen DG
  6. Rowley JD
  7. Nucifora G
  Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression nof co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigneic properties; Current Topics in Microbiology & Immunology; Vol 211, pp. 243-52. 1996 Jan 01.
• 1. Zent C
  2. Smith P
  Drug allergy; S AFr Med J; Vol 84(5), pp. 281-286. 1994 Jan 01.
• 1. Zent CS
  Toxicity of anti-tuberculous medication; S. Afr J of Epidemiology and Infection; Vol 9(1), pp. 5-9. 1994 Jan 01.
• 1. Zent CS
  2. Allin R
  3. Folb PI
  Prediction of amikacin dose requirements in neutropenic patients with haematological disease; S. Afr Med J; Vol 82(11), pp. 853-854. 1993 Jan 01.